Commentary on "comparative effectiveness of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial." B.I. Rini, B. Escudier, P. Tomczak, A. Kaprin, C. Szczylik, T.E. Hutson, M.D. Michaelson, V.A. Gorbunova, M.E. Gore, I.G. Rusakov, S. Negrier,
Y.C. Ou, D. Castellano, H.
Y. Lim, H. Uemura, J. Tarazi, D. Cella, C.
Chen, B. Rosbrook, S. Kim, R.J. Motzer: Lancet 2011;378:1931-9 [Epub;2011, November 4].
Trump DL. Urol Oncol. 2012 Sep; 30(5):748.